Health and Fitness Health and Fitness
Wed, November 2, 2011
[ Wed, Nov 02nd 2011 ] - Market Wire
Bellicum Announces Publication in The New England .. ating Complete Reversal of Serious Immune Conditi
[ Wed, Nov 02nd 2011 ] - Market Wire
Nuvo Research Announces 2011 Third Quarter Results
[ Wed, Nov 02nd 2011 ] - Market Wire
Cadence Pharmaceuticals' CEO Ted Schroeder to Pre .. Suisse Healthcare Conference on November 9, 2011
[ Wed, Nov 02nd 2011 ] - Market Wire
Edwards Lifesciences Receives FDA Approval for First Catheter-Based Aortic Heart Valve in the U.S.
[ Wed, Nov 02nd 2011 ] - Market Wire
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
[ Wed, Nov 02nd 2011 ] - Market Wire
Sun Healthcare Group, Inc. to Present at the 2011 Credit Suisse Healthcare Conference
[ Wed, Nov 02nd 2011 ] - Market Wire
The Medicines Company Announces Schedule of Event .. eter Cardiovascular Therapeutics (TCT) Conference
[ Wed, Nov 02nd 2011 ] - Market Wire
Atrion Reports Third Quarter Results
[ Wed, Nov 02nd 2011 ] - Market Wire
Syneron to Participate in Three Upcoming Investor Conferences
[ Wed, Nov 02nd 2011 ] - Market Wire
Hansen Medical Reports Third Quarter and Nine-Month 2011 Results
[ Wed, Nov 02nd 2011 ] - Market Wire
Dynavax Announces Proposed Public Offering of Common Stock
[ Wed, Nov 02nd 2011 ] - Market Wire
Diagnostic Breakthrough in Multiple Sclerosis Wit .. Noninvasive Treatment That Results in Symptoms of
[ Wed, Nov 02nd 2011 ] - Market Wire
Stellar Biotechnologies to Submit Documents for Registration of Shares in the U.S.
[ Wed, Nov 02nd 2011 ] - Market Wire
NuPathe Appoints Bart J. Dunn as Vice President, Corporate Development &;; Licensing
[ Wed, Nov 02nd 2011 ] - Market Wire
BIOLASE to Present at WJB Capital Group's Laser Company -- Management Access Event
[ Wed, Nov 02nd 2011 ] - Market Wire
Graymark Healthcare to Present at the Southwest IDEAS Investor Conference on November 16, 2011
[ Wed, Nov 02nd 2011 ] - Market Wire
ProPhase Labs to Release Third Quarter Results on Wednesday, November 9th
[ Wed, Nov 02nd 2011 ] - Market Wire
Faster FDA Review Process Bodes Well for NPS Pharmaceuticals and Cel-Sci Corp
[ Wed, Nov 02nd 2011 ] - Market Wire
Faster FDA Drug Reviews Should Benefit Cardium Therapeutics and CytRx Corporation
[ Wed, Nov 02nd 2011 ] - Market Wire
Equity Research on Elan Corp. plc and Hospira Inc. - Fortunes Change Quickly in Drug Delivery
[ Wed, Nov 02nd 2011 ] - Market Wire
IBEX Reports Q4 and Fiscal 2011 Results
[ Wed, Nov 02nd 2011 ] - Market Wire
Marina Biotech Demonstrates That Its Novel UsiRNA .. totoxicity Resulting From microRNA-Like Off-Targe
[ Wed, Nov 02nd 2011 ] - Market Wire
Given Imaging Announces New Data Underscore Value of ManoScan(TM) AR in Patients With Incontinence
[ Wed, Nov 02nd 2011 ] - Market Wire
Implant Sciences Signs Cooperative Research && .. nt With TSL S&;;T, a Directorate of the
[ Wed, Nov 02nd 2011 ] - Market Wire
Medivation Announces Third Quarter Financial Resu .. ts Teleconference and Webcast on November 9, 2011
[ Wed, Nov 02nd 2011 ] - Market Wire
MELA Sciences Announces FDA Approval for MelaFind(R)
[ Wed, Nov 02nd 2011 ] - Market Wire
New Studies Show GERD Is Best Assessed Off PPI Therapy
[ Wed, Nov 02nd 2011 ] - Market Wire
Threshold Pharmaceuticals Appoints Nipun Davar as .. t of Pharmaceutical Development and Manufacturing
Tue, November 1, 2011
[ Tue, Nov 01st 2011 ] - Market Wire
Experts Report that Abbott's New PLEX-ID Assay Of .. ortant Testing Capabilities for Biothreat Defense
[ Tue, Nov 01st 2011 ] - Market Wire
Alkermes' Corporate Presentation to be Webcast at 2011 Annual Credit Suisse Health Care Conference

Alkermes' Corporate Presentation to be Webcast at 2011 Annual Credit Suisse Health Care Conference


Published on 2011-11-01 22:40:58 - Market Wire
  Print publication without navigation


DUBLIN--([ BUSINESS WIRE ])--[ Alkermes plc ] (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse Health Care Conference on Wednesday, Nov. 9, 2011, at 10:30 a.m. MST (12:30 p.m. EST/5:30 p.m. GMT) from the Arizona Biltmore Hotel in Phoenix, Arizona. The presentation may be accessed from the investor relations section on [ www.alkermes.com ] and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermesa website at [ www.alkermes.com ].

Contributing Sources